This morning I was surprised to read that some health care professionals are worried that Lantus may be linked with Cancer. In an article published by Bloomberg, a UBS analyst said that while they could not confirm any risk they “hear a number of long-established safety concerns, in particular that Lantus use may promote cancer.”
Read more
I seriously hope that is in no way true 
Lantus is what my boyfriend takes at night, 45 units…
whew that’d be all he needs to hear …
Indeed, Henry.
Here is a press release I just received from the International Diabetes Federation about this:
Statement from the International Diabetes Federation Related to Studies Published in Diabetelogia Suggesting Possible Link Between Insulin Glargine and Cancer
The International Diabetes Federation (IDF) today called for urgent assessment and responses from regulatory authorities into a possible link between the use of insulin glargine (an insulin analogue) and increased risk of cancer based on findings published on 26 June, 2009 in Diabetelogia, the journal of the European Association for the Study of Diabetes (EASD).
The online data published in Diabetelogia is based on four studies relating to a possible link between a long-acting insulin analogue, insulin glargine and cancer. According to EASD, the findings are based on evidence from studies in Germany, Sweden, Scotland and the United Kingdom. The studies however, are not conclusive.
The International Diabetes Federation understands the concern about the Diabetelogia study findings but urges the diabetes community to wait for the current scientific information to be released and calls for urgent further scientific studies to be undertaken in other countries.
The International Diabetes Federation stresses that it is important that people needing insulin do not stop taking the drug. IDF cautioned that people with diabetes should see their doctor for advice before considering any change to their treatment.
European Association for the Study of Diabetes Here is a webcast by Professor Ulf Smith (University of Göteborg, Sweden), and Professor Edwin Gale (University of Bristol, UK). (transcript) “…Lantus users fell into two fairly distinct groups – those who took Lantus with other insulins, most of whom were relatively young and had type 1 diabetes, and those who were on Lantus alone, who were older and had type 2 diabetes. The first group had a lower than average cancer risk, as compared with human insulin, and the group on Lantus alone had a slightly higher risk…the investigators concerned consider the results to be far from conclusive…”